Article
Email Email Print Print
Clip Clip & File

Only on Che.com :: Latest News

January 8, 2013

Lonza to expand ADC manufacturing capacity

Gerald Ondrey

Lonza (Basel, Switzerland; www.lonza.com) plans to invest CHF14 million (about $15 million) to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years. 

Because cGMP manufacturing of ADCs presents unique challenges, facilities must be designed to handle both biological species and highly potent cytotoxic small molecule drugs. Lonza has been a pioneer in the manufacturing of ADCs since its initial investment in 2006 which established manufacturing suites for both small and large scale projects, dedicated Research & Development labs, and Quality Control facilities specifically for ADCs. Since 2010, Lonza has validated large scale manufacturing of platform technologies primarily utilized by ADC drug developers. 

The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption. It is the next step in bringing challenging new technologies to one of Lonza’s main sites. The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp. 

“We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers” says Stefan Stoffel, head of Lonza’s Chemical Manufacturing business unit. “Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics. In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites.” 

 

Add a Comment

Name:
Email:
Comments:

Please enter the letters or numbers you see in the image. (refresh)
 
 

Related Stories

LinkedIn Groups

Our LinkedIn group is now over 30,000 members strong!

  1. Join other CPI professionals from all over the globe and share best practices, expertise, concerns and more.
  2. Provide feedback to Chemical Engineering Editors


Current members represent Worley Parsons, DuPont, SABIC, Fluor, Air Products, LyondellBasell, Nalco, Dow Chemical, Dow Corning, BASF, Jacobs Engineering, ExxonMobil, Shell, Chevron and more.

Join Now



We also offer the following subgroup for more targeted discussions:

Tools
Search the Buyers' Guide

Plant Cost Index

Facts at Your Fingertips (archive)

Ask the Experts

Back Issues
X
To access this area, please log in or create an account.
Username:
Password:
Forgot your password?
Request it now.
Processing...
Live chat by BoldChat